

I. Scifinder

➤ 搜尋主題：**Thalidomide 的 Angiogenesis 抗癌新作用**

Thalidomide 是身為藥學人耳熟能詳的老藥，早在 1950 年代，就被廣泛使用為鎮靜劑及預防妊娠性嘔吐，但因後來發現會使懷孕婦女產下畸型胎(海豹肢)而使其被列為禁藥，從此 thalidomide 便在臨床上消聲匿跡，在國內更因此未曾上市。但某次藥理課時老師提到此藥時補充說，近年來此藥又被發現有抑制癌細胞血管新生的獨特藥理特性，及抑制發炎與免疫調節作用而具有抗癌用途，因此我希望藉由 scifinder 找尋更多關於此藥的資訊與新用途…。

※ 搜尋成果

具三大項搜尋功能：*Explore references*、*Explore substances* 與 *Explore reactions*

首先利用其中一項搜尋功能—Explore substances

登入 scifinder 頁面後於 explore substances 中先了解 Thalidomide 的基本結構與特性

SciFinder - Substance Answer Set - Windows Internet Explorer

https://origin-scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf

Explore References Explore Substances Explore Reactions

Welcome Amy Chou | Sign Out

Substance Identifier "Thalidomide" > substances (1) 以Thalidomide檢索後得到一筆物質資料

Substances Get References Get Reactions Tools Send to SciPlanner

1 Substance 0 Selected Save Print Export

Select All Deselect All Sort by: CAS Registry Number

1. Substance Detail 50-35-1

O=C1NC(=O)c2ccccc2N1C(=O)N3CCCC(=O)N3

C₁₃ H₁₀ N₂ O₄

1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-

~4,259 References

下出現結構圖,點進去看看

Analysis Refine

Analyze by: Substance Role

Click bar to view only those substances within the current answer set

Analytical Study 1

Biological Study 1

Formation, Nonpreparative 1

Miscellaneous 1

Occurrence 1

Preparation 1

Process 1

Properties 1

可將結構圖放入 SciPlanner 中等日後編纂在一起

Substance Detail

CAS Registry Number: 50-35-1

C13H10N2O4

1H-Isindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-

Phthalimide, N-(2,6-dioxo-3-piperidinyl)- (6Cl,7Cl,8Cl); (±)-Thalidomide; 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)isindoline; 3-Phthalimidoglutaramide; Celgene; Contergan; Distaval; K 17; Kevadon; Myrin; N-(2,6-Dioxo-3-piperidinyl)phthalimide; N-Phthalylglutaramide; NSC 527179; NSC 66847; Neurosedyn; Pantosediv; Pharmion; Quetimid; Sauramide; Sedalis; Sedoval; Softenil; Softenon; Suaramide; Synovir; Talimol; Talinol; Thaled; Thalidomide; Thalomid; α-(N-Phthalimido)glutaramide; α-N-Phthalylglutaramide; α-Phthalimidoglutaramide

Deleted CAS Registry Numbers: 731-40-8;14088-68-7

~4,259 References

Document Types: Book, Conference, Dissertation, Journal, Patent, Report

CAS Role	Patents	Nonpatents	Nonspecific Derivatives from Patents	Nonspecific Derivatives from Nonpatents
Analytical Study	✓	✓	✓	✓

結構圖、化學式與其他名稱

其下尚有專利情形與各種物理性質的介紹可繼續往下拉捲軸

~4,259 References

Document Types: Book, Conference, Dissertation, Journal, Patent, Report

CAS Role	Patents	Nonpatents	Nonspecific Derivatives from Patents	Nonspecific Derivatives from Nonpatents
Analytical Study	✓	✓	✓	✓
Biological Study	✓	✓	✓	✓
Formation, Nonpreparative		✓		✓
Miscellaneous		✓		✓
Occurrence		✓		
Preparation	✓	✓	✓	✓
Process	✓	✓	✓	✓
Properties	✓	✓	✓	✓
Prophetic in Patents	✓			
Reactant or Reagent	✓	✓		✓
Uses	✓	✓	✓	✓

由此可知 Thalidomide在各領域被專利的情形

Predicted Properties: Biological Chemical Density Lipinski and Related Spectra Structure-related Thermal

Biological Properties	Value	Condition	Note	Top
Bioconcentration Factor	1.05	pH 1 Temp: 25 °C	(24)	
Bioconcentration Factor	1.05	pH 2 Temp: 25 °C	(24)	
Bioconcentration Factor	1.05	pH 3 Temp: 25 °C	(24)	
Bioconcentration Factor	1.05	pH 4 Temp: 25 °C	(24)	
Bioconcentration Factor	1.05	pH 5 Temp: 25 °C	(24)	

SciFinder - Substance Answer Set - Windows Internet Explorer

https://origin-scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf

Google

SciFinder - Substance Answer Set

Welcome Amy Chou | Sign Out

Add KMP Alert Substance Identifier "Thalidomide"

Substances

1 Substance 0 Selected

1 Substance sent to SciPlanner.

Select All Deselect All Sort by: CAS Registry Number

1. Substance Detail 50-35-1

O=C1NC(=O)c2ccccc2N1C3=CC=CC=C3

C₁₃ H₁₀ N₂ O₄

1H-Isindole-1,3(2H)-dione, 2-(2,6-dimox-3-ninoridinyl)-

CAS Registry Number: 50-35-1

View Substance Detail

Explore by Structure

Synthesize this...

Get Reactions where Substance is a...

Get Commercial Sources

Get Regulatory Information

Get References

Export as Image

Send to SciPlanner

Analysis

Refine

Analyze by:

Substance Role

Analytical Study 1

Biological Study 1

Formation, Nonpreparative 1

Miscellaneous 1

Occurrence 1

Preparation 1

Process 1

在結構圖的右上角點一下可看到很多有關這物質的相關合成或資料，可以一併點入並放入 SciPlanner 中或另外點前面所說的三大功能再打關鍵字。

利用另一項搜尋功能—Explore references

SciFinder - Explore References - Windows Internet Explorer

https://origin-scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf

Google

SciFinder - Explore References

Welcome Amy Chou | Sign Out

Add KMP Alert Substance Identifier "Thalidomide" > substances (1) > 50-35-1 > 2008:747831

Explore References

Research Topic

Thalidomide

Search

Publication Year(s)

1995-1999

Document Type(s)

Biography

Book

Clinical Trial

Commentary

Dissertation

Editorial

Historical

Journal

Patent

Preprint

Report

Review

Saved Answer Sets

No answer sets

Import

Keep Me Posted Results

No profiles exist

SciFinder - Reference Answer Set - Windows Internet Explorer

https://origin-scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf

SciFinder®

Welcome Amy Chou | Sign Out

Add KMP Alert Research Topic "Thalidomide" > references (11849)

References Get Substances Get Reactions Get Related Tools Send to SciPlanner

11849 References 0 Selected Save Print Export

Duplicates were not automatically removed. Answer set exceeds 10,000 reference limit.

Select All Deselect All Sort by: Accession Number Answers per Page [20] 1 2 3 4 5 6 ... 593 Display: [List Icon]

1. Dihydroxypentamethoxyflavone down-regulates constitutive and inducible signal transducers and activators of transcription-3 through the induction of tyrosine phosphatase SHP-1
By Phromnoi, Kanokkarn; Prasad, Sahdeo; Gupta, Subash C.; Kannappan, Ramaswamy; Reuter, Simone; Limtrakul, Porngarn; Aggarwal, Bharat B.
From Molecular Pharmacology (2011), 80(5), 889-899. Language: English, Database: CAPLUS
Because constitutive activation of signal transducers and activators of transcription-3 (STAT3) has been linked with cellular transformation, survival, proliferation, chemoresistance, and angiogenesis of various tumor cells, agents that can suppress STAT3 activation have potential as cancer therapeutics. In the present report, we identified a flavone from the leaves of a Thai plant, *Gardenia obtusifolia*, 5,3'-dihydroxy-3,6,7,8,4'-pentamethoxyflavone (PMF), that has the ability to inhibit STAT3 activation. PMF inhibited both constitutive and interleukin-6-inducible STAT3 activation in multipl...

2. Combining the Ras inhibitor salirasib and proteasome inhibitors: a potential treatment for multiple myeloma
By Yaari-Stark, Shiraj; Nevo-Caspi, Yael; Jacob-Hirsch, Jasmine; Rechavi, Gideon; Nagler, Arnon; Kloog, Yoel
From Journal of Cancer Science & Therapy (2011), 3(8), 1000186. Language: English, Database: CAPLUS
Multiple myeloma (MM) is an incurable disease that develops resistance to chemotherapy. New treatments with thalidomide or bortezomib are partially successful. Drug resistance, differentiation block, and increased survival in MM result from genomic alterations, including high overexpression of cyclin D and fibroblast growth factor receptor 3 (FGFR3) and mutations in NRas. Oncogenic Ras isoforms can be inhibited by the Ras inhibitor

Refine by: Research Topic Author Name Company Name Document Type Publication Year Language Database

輸入angiogenesis

Research Topic

Examples: The effect of antibiotic residues on dairy products Photocyanation of aromatic compounds

Refine

當經過 refine 後會找出我想要的有關同時有 Thalidomide 與 Angiogenesis 相關的資料

SciFinder - Reference Answer Set - Windows Internet Explorer

https://origin-scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf

SciFinder®

2. Treatment effect and influence on the level of angiogenesis-associated factors in acute leukemia treated by thalidomide
By Zhai, Xinhui; Wei, Xucang; Wang, Yi; Zhao, Yuan; Lian, Xiaoyun; Zhang, Ding; Miao, Yudi
From Baixuebing Linbalu (2011), 20(8), 486-489. Language: Chinese, Database: CAPLUS
The clin. effect and the influence of the level of plasma vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR) and basic fibroblast growth factor (bFGF) in acute leukemia before and after treatment by thalidomide combined with chemotherapy were obsd. Thirty-six cases of acute leukemia patients were randomly divided into exptl. group and control group by 18 cases each. Each group was treated with conventional chemotherapy in the std.-dose, meanwhile in the exptl. group addnl. thalidomide 100 mg/day were taken orally. Before treatment and 8 wk after t...

3. Thalidomide inhibits the proliferation of cultured vascular endothelial cells by inducing G1 arrest and apoptosis
By Chi, Xiao-Yan; Qu, Ming-Juan; Wang, Yan-Hua; Han, Li-Ya
From Zhongguo Shengwu Huaxue Yu Fenzi Shengwu Xuebao (2011), 27(9), 827-832. Language: Chinese, Database: CAPLUS
Thalidomide is an anti-angiogenic drug and clin. used in a no. of cancers. However, the mechanism of anti-angiogenesis is poorly understood. In this study, we have obsd. that thalidomide inhibited the proliferation of vascular endothelial cells in vitro as shown by MTT assays. The IC50 value of thalidomide was 16.47 µg/mL. Hoechst staining and flow cytometry (FCM) were used to examine cellular apoptosis and cell cycle alterations. The result showed that thalidomide reduced apoptosis and arrested cell cycle in the G/G1 phase. The Bcl-2 expression was markedly decreased with higher thalidom...

4. Methods of treating breast cancer by modulating signal transduction regulated by β-arrestin
By Shenoy, Sudhar; Dewhirst, Mark; Han, Sang-Oh
From PCT Int. Appl. (2011), WO 201113210 A2 20111027. Language: English, Database: CAPLUS
The invention relates, in general, to breast cancer and, in particular, to methods of treating breast cancer comprising administering to a subject in need thereof an agent that modulates signal transduction regulated by β-arrestin (e.g., β-arrestin 1). The invention further relates to methods of identifying compds. suitable for use in such methods.

Rajkumar S V 21

Rajkumar S Vincent 21

Zeldis Jerome B 19

Hideshima Teru 17

Zangari Maurizio 16

Dahut William L 15

Show More

Categorize

More detailed analysis based on CAS indexing

Categorize

點選其中與自己主題相符的一篇進入而得（點選 Get full Text 可得完整資料）

SciFinder - Thalidomide inh... - Windows Internet Explorer

https://origin.scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf

檔案(F) 編輯(E) 檢視(V) 我的最愛(A) 工具(T) 說明(H)

Google 搜尋 更多設定 >>

我的最愛 建議的網站 自訂連結 免費的 Hotmail 百度 網頁快訊圖庫

SciFinder - Thalidomide inh...

Google 這是英文網頁，需要「Google 工具列」為您翻譯嗎？不是「英文」的網頁嗎？協助我們進行改進 系統將透過安全連線，將此安全網頁的內容傳送給 Google 翻譯。 瞭解詳情

SciFinder®

Welcome Amy Chou | Sign Out

Add KMP Alert Research Topic "Thalidomide" > references (11849) > refine "angiogenesis" (1818) > Thalidomide inhibits the proli...

Reference Detail Get Substances Get Reactions Get Cited Get Citing Get Full Text Send to SciPlanner

Link Save Print Export

Return Previous Next

3. Thalidomide inhibits the proliferation of cultured vascular endothelial cells by inducing G1 arrest and apoptosis

By: Chi, Xiao-Yan; Qu, Ming-Juan; Wang, Yan-Hua; Han, Li-Ya

Thalidomide is an anti-angiogenic drug and clin. used in a no. of cancers. However, the mechanism of anti-angiogenesis is poorly understood. In this study, we have obsd. that thalidomide inhibited the proliferation of vascular endothelial cells in vitro as shown by MTT assays. The IC50 value of thalidomide was 16.47 µg/mL. Hoechst staining and flow cytometry (FCM) were used to examine cellular apoptosis and cell cycle alterations. The result showed that thalidomide reduced apoptosis and arrested cell cycle in the G/G1 phase. The Bcl-2 expression was markedly decreased with higher thalidomide concns. as analyzed by Western blotting. Our discovery indicated that thalidomide inhibited the regeneration of endothelial cells possibly by repressing expression of anti-apoptotic Bcl-2 and activating the signaling pathway of G1 phase. The underlining mechanism is deserved for further studies and may help to understand the inhibition of thalidomide in tumor growth. The specific mechanism of endothelial cell apoptosis and G1 phase arrest is in the study.

Indevinn

Quick Links

0 Tags, 0 Comments

Source

Zhongguo Shengwu Huaxue Yu Fenzi Shengwu Xuebao
Volume 27
Issue 9
Pages 827-832
Journal
2011
CODEN: ZSHXF2
ISSN: 1007-7626

Company/Organization

School of Life Sciences
Ludong University
Yantai, Peop. Rep. China 264025

SciFinder - Treatment effec... - Windows Internet Explorer

https://origin.scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf

檔案(F) 編輯(E) 檢視(V) 我的最愛(A) 工具(T) 說明(H)

Google 搜尋 更多設定 >>

我的最愛 建議的網站 自訂連結 免費的 Hotmail 百度 網頁快訊圖庫

SciFinder - Treatment effec...

Google 這是英文網頁，需要「Google 工具列」為您翻譯嗎？不是「英文」的網頁嗎？協助我們進行改進 系統將透過安全連線，將此安全網頁的內容傳送給 Google 翻譯。 瞭解詳情

SciFinder®

Welcome Amy Chou | Sign Out

Add KMP Alert Research Topic "Thalidomide" > references (11849) > refine "angiogenesis" (1818) > Treatment effect and influence on the level of angiogenesis-associated factors in acute leukemia treated by thalidomide

Reference Detail Get Substances Get Reactions Get Cited Get Citing Get Full Text Send to SciPlanner

Link Save Print Export

Return Previous Next

2. Treatment effect and influence on the level of angiogenesis-associated factors in acute leukemia treated by thalidomide

By: Zhai, Xinhui; Wei, Xucang; Wang, Yi; Zhao, Yuan; Lian, Xiaoyun; Zhang, Ding; Mao, Yudi

The clin. effect and the influence of the level of plasma vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGFR) and basic fibroblast growth factor (bFGF) in acute leukemia before and after treatment by thalidomide combined with chemotherapy were obsd. Thirty-six cases of acute leukemia patients were randomly divided into exptl. group and control group by 18 cases each. Each group was treated with conventional chemotherapy in the std.-dose, meanwhile in the exptl. group addnl. thalidomide 100 mg/day were taken orally. Before treatment and 8 wk after treatment, plasma was collected for the detection of VEGF, VEGFR and bFGF contents by double antibody sandwich ELISA (ELISA). The ratios of exptl. group and control group were 88.9% (16/18), 77.8% (14/18) resp. and the difference was statistically significant ($\chi^2=4.103$, $P<0.05$). The level of plasma VEGF (389.78±249.94 pg/mL, 318.54±125.78 pg/mL) of exptl. group and control group before treatment was statistically significant ($t=3.141$, $t=3.024$, $P<0.01$) compared with healthy group [(132.91±26.66) pg/mL] resp. The level of plasma VEGF of those groups after treatment [(211.74±36.72) pg/mL, (288.02±31.77) pg/mL] was statistically significant ($t=2.413$, $t=2.324$, $P<0.05$) compared with healthy group resp. The difference of the level of plasma VEGF of exptl. group and control group before treatment was not statistically significant ($t=1.384$, $P>0.05$). The difference of the level of plasma VEGF of exptl. group and control group after treatment was statistically significant ($t=2.793$, $P<0.05$). The level of plasma VEGFR [(2490.75±1695.9) pg/mL, (2322.78±1105.87) pg/mL] of exptl. group and control group before treatment was statistically significant ($t=2.914$, $t=2.783$, $P<0.01$) compared with healthy group [(1134.98±378.45) pg/mL] resp. The level of plasma VEGFR of those groups after treatment [(1359.71±390.24) pg/mL, (1753.89±337.04) pg/mL] was statistically significant ($t=2.572$, $t=2.447$, $P<0.05$) compared with healthy group resp. The difference of the level of plasma VEGFR of exptl. group and control group before treatment was not statistically significant ($t=1.276$, $P>0.05$). The difference of the level of plasma VEGFR of exptl. group and control group after treatment was statistically significant ($t=2.486$, $P<0.05$). The level of plasma bFGF [(2.43±0.27) ng/mL, (2.41±0.33) ng/mL] of exptl. group and control group before treatment was statistically significant ($t=4.982$, $t=4.171$, $P<0.05$) compared with healthy group (1.83±0.44) ng/mL resp.; and the level of plasma bFGF of those groups after treatment [(2.09±0.17) ng/mL, (2.11±0.31) ng/mL] was statistically significant ($t=3.011$, $t=2.773$, $P<0.05$) compared with healthy group resp. The difference of the level of plasma bFGF of exptl. group and control group before treatment was not statistically significant ($t=0.953$, $P>0.05$). The difference of the level of plasma bFGF of exptl. group and control group after treatment was

Accession Number

2011:1421099
CAPLUS

Publisher

Baixuebing Linbaliu Zazhi Bianjibu

利用第三項搜尋功能—Explore reactions

SciFinder - Reaction Answer Set - Windows Internet Explorer

https://scifinder.cas.org/scifinder/view/scifinder/scifinder/Explore.jsf

thomson innovation

SciFinder®

Welcome Amy Chou | Sign Out

Substance Identifier "Thalidomide" > substances (1) > get reactions (58)

Reactions

58 Reactions 0 Selected

Sort by: Accession Number

Answers per Page [15]

Display:

1. View Reaction Detail [Link](#)

4 Steps Hover over any structure for more options.

列出合成反應式

Reaction scheme showing the synthesis of a benzimidazole derivative from cyclopentenone, acetic anhydride, and benzimidazole.

Analysis

Analyze by:

Catalyst

Click bar to view only those reactions within the current answer set

Catalyst	Count
Fe(NO ₃) ₃	6
4-DMAP	3
RuCl ₃ · xH ₂ O	3
PdCl ₂	2
SiO ₂	1

Show More


可將以上自己需要的資料、物質結構、反應機構”send to sciplanner” 去統一編纂在一起之後可統一彙整出來一份完整的相關主題資料。

II. THOMSON Innovation


➤ 搜尋主題：multi-touch 多點式觸控

multi-touch 多點式觸控是近期很受歡迎的面板新科技，這種介面技術可以取代目前所使用的鍵盤（按鈕）、滑鼠，將進一步體現出人性化操控介面的未來趨勢，連 iphone、ipad 也積極開發，因此我想藉這此機會利用 THOMSON INNOVATION 找出相關專利…。

登入後打上關鍵字



搜尋到的成果(顯示專利號、標題、時間)




The screenshot shows the Thomson Innovation Patent Result Set page. The search criteria are Patents with the keyword 'printer'. The results list 4,685 records. The table displays the following information:

Publication Number	Publication Date	
US8077153B2	2011-12-13	
Title: Precise selection techniques for multi-touch screens		
US8075135B2	2011-12-13	
Title: Peripheral vision training and/or testing during central vision fixation		
US8074172B2	2011-12-06	
Title: Method, system, and graphical user interface for providing word recommendations		
US8073980B2	2011-12-06	
Title: Methods and systems for automatic configuration of peripherals		
US8072437B2	2011-12-06	
Title: Flexible multitouch electroluminescent display		
US8072429B2	2011-12-06	
Title: Multi-axial touch-sensor device with multi-touch resolution		
US8065624B2	2011-11-22	

The page also includes a sidebar with navigation options like Search, My Account, and Support. The bottom of the page shows the Thomson Reuters logo and a status bar with the time 11:31.

點進去的内容後可快速瀏覽，旁邊有圖示



The screenshot shows the Thomson Innovation Record View page for Patent US8077153B2. The page includes a sidebar with navigation options like Add to Work File, Mark Record, Watch Record, Download, and Print. The main content area displays the patent details:

Record View: Patent US8077153B2

Quick View 可快速瀏覽是否為自己要找的專利

DWPI Title ?
Pixel-accurate targeting facilitating system for a multi-touch sensitive screen of e.g. a desktop computer has multi-touch tracking component that tracks and disambiguates multi-touch input from primary and secondary fingers

Original Title ?
Precise selection techniques for multi-touch screens

Abstract ?
A unique system and method is provided that facilitates pixel-accurate targeting with respect to multi-touch sensitive displays when selecting or viewing content with a cursor. In particular, the system and method can track dual inputs from a primary finger and a secondary finger, for example. The primary finger can control movement of the cursor while the secondary finger can adjust a control-display ratio of the screen. As a result, cursor steering and selection of an assistance mode can be performed at about the same time or concurrently. In addition, the system and method can stabilize a cursor position at a top middle point of a user's finger in order to mitigate clicking errors when making a selection.

First Claim ?
1. A system that facilitates pixel-accurate targeting with respect to a multi-touch sensitive screen comprising:
• a multi-touch tracking component that tracks multi-touch input comprising input

The right side of the page features a diagram titled "Images" showing a flowchart of the system. The flowchart includes a "MULTI-TOUCH OR DUAL MEMBER INPUT" block, a "MULTI-TOUCH TRACKING COMPONENT" block (labeled 110), a "CURSOR CONTROL COMPONENT" block (labeled 120), and a "VISUALIZE CHANGE IN CURSOR SPEED, POSITION, OR CONTENT UNDERLYING THE CURSOR" block. The diagram also includes a "Zoom (+)" button and a "Full View" button.

再點右上角的”full view”可看更多相關細節

※ 使用心得

I. Scifinder

整個使用完 scifinder 的過程後，發現他真的是個很好用的搜尋資源，不免有種相見恨晚的感覺。像這次搜尋 Thalidomide 的 Angiogenesis 抗癌新作用，一開始打 Thalidomide 去搜尋時會有很多資料，但若使用”refine” 再加上 Angiogenesis 的關鍵字就真的可以找到 Thalidomide 的 Angiogenesis 作用，各種 paper 的研究不管是從藥理機轉的探討還是藥化結構下去看，scifinder 的搜尋範圍十分廣泛，只要是關鍵字打得夠精確，scifinder 就能找出我們要的還可以按照出版年限排，非常好用。

另一個令人驚奇的設計就是他除了能幫你找出搜尋物質的結構，尚有相關反應化學的合成（對在學有機與藥化真的很有用），還可以整理出這個物質相關研究是否有被專利，讓真正想參與研究的人不會白忙一場可以分散風險，另有可以畫結構的畫板，讓我們直接在電腦上模擬想合成的結構再去尋找相關反應式，節省了

不少寶貴的時間在實驗的嘗試上。

我很喜歡它的另外的編輯軟體 sciplanner，可以把所有確定要的資料、結構、反應式儲存起來最後再一起編輯匯出，讓我們都能很有效率的去使用要的資料不會漏了哪個，也可以放在一起比較，最後可能很多資料匯出時可以只有真正我們需要的，使找尋資料能去蕪存菁，真的是十分貼心的設計。

希望學校能繼續撥經費讓學生擁有 scifinder 的使用權，且若有計畫的推廣讓我們在大一或大二時即接觸到這系統也許對我們的幫助能更早，也是提供學生另一課後自修的管道。

II. THOMSON Innovation

最近的新聞才在報導：為加速處理專利權申請，經濟部智慧財產局將招募專利審查人才，大學畢業新鮮人每月待遇 4 萬 9 千元；大學畢業並具兩年工作經驗，或碩士畢業則有 5 萬 1 千元待遇。凡具備機械、電子、資訊、化學、光電、電信、材料工程、藥學、生物技術、電力工程、物理、食品、醫學工程及紡織工程等 14 類專業，符合資格者，皆可上智慧局網站報名徵選。因此，在邊做這次 innovation 的作業搜尋時感覺格外慶幸，這次學到了把專利申請整理得那麼好的系統，結合國際上已發表的專利讓我們用關鍵字即可搜尋，而且更新速度非常快即時呈現專利文件，因此學會運用此系統相信能給自己的未來用多了項潛力與可能。

可惜的是這次學生沒有帳號可以再更進階使用其他功能，希望學校可以在做接洽讓這項系統在北醫能被推廣使用，也許也可以開類似專利研究的專門課程供大家選修，畢竟專利審核是一項新的領域，除了有學校有開相關研究所外，政府部門也開類似職缺，若在學校能修習能夠結合 scifinder、THOMSON Innovation 或其他相關系統的課程除了讓學生日後作研究更方便外，也許也可以培養學生另一項強項與專業。